Mitrotan (Ergometrine Maleate)

Ergometrine maleate acts as a partial agonist at serotonin (5‑HT2), dopamine and alpha‑adrenergic receptors in the uterine smooth muscle. This multi‑receptor activation increases intracellular calcium, producing a strong and lasting contraction of the myometrium that limits postpartum blood loss.

The dose of Mitrotan is determined by the prescribing clinician based on the patient’s clinical condition, severity of hemorrhage, and local treatment protocols. Healthcare professionals should follow the recommended dosing guidelines provided in the product’s prescribing information.

Mitrotan is intended for use after delivery; it is not recommended for use during pregnancy because uterine stimulation before birth could be harmful. Limited data are available for breastfeeding, so clinicians should weigh potential risks and benefits before prescribing to nursing mothers.

To order Mitrotan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative uterotonic is oxytocin, which is a peptide administered intravenously or intramuscularly. Mitrotan, an oral ergot alkaloid, offers a different route of administration and a longer duration of uterine contraction, but it carries a higher risk of vasoconstrictive side effects compared with oxytocin.

Mitrotan tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Mitrotan is supplied as oral tablets and should be taken by mouth with a glass of water. The tablet is swallowed whole; it is not intended to be crushed, chewed, or dissolved unless specifically directed by a healthcare professional.

The most serious adverse events associated with Mitrotan include severe hypertension, cardiac arrhythmias, and pulmonary edema. Patients should be monitored closely for sudden spikes in blood pressure, irregular heart rhythms, or respiratory distress, and treatment should be stopped if these events occur.

Mitrotan is contraindicated in individuals with known hypersensitivity to ergot alkaloids, uncontrolled hypertension, pre‑eclampsia, or those currently taking monoamine oxidase inhibitors. It should also be avoided in patients with severe cardiovascular disease where additional vasoconstriction could be dangerous.